Eton Pharmaceuticals Inc (ETON)
Featured in
High-Growth Small-Cap Stocks
Eton Pharmaceuticals Inc. is a NASDAQ-listed common stock issuer in the healthcare sector focused on pharmaceuticals. The company develops and commercializes medicines for rare diseases and markets several approved products, including treatments used for severe primary IGF-1 deficiency, adrenal insufficiency, adrenocortical insufficiency, Wilson disease, phenylketonuria, N-acetylglutamate synthase deficiency, homocystinuria, and tyrosinemia type 1. Eton also has a pipeline of late-stage product candidates such as ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector. Incorporated in 2017, the company is based in Deer Park, Illinois.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ETON
|
$52.88
|
-7.4% Downside
|
Fair
|
$71
|
24.4% Upside
|
Undervalued
|
Great
|
0.0%
|
November 5, 2026
|
128.6x
|
35.0x
|
15.5x
|
1.632 B
|
1.634 B
|
1.8%
|
78.0%
|
14.9
|
116.1%
|
